AUPH

Aurinia Pharmaceuticals

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$392M

Burn Rate (Qtr)

$34.1M

Company Profile

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerularsclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES).

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Voclosporin

Lupus Nephritis

PDUFA

Jan 22, 2021

Voclosporin Ophthalmic Solution

Dry Eye Syndrome

Discontinued

Voclosporin

Focal Segmental Glomerulosclerosis (FSGS)

Phase 2 (Interim Data)

H2 2020

Recent Posts

See what the community is saying - click to see full post

AUPH - Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome

AUPH Ph3 data in lupus nephritis impresses investors

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon